A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer

The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from a Belgian healthcare payer’s perspective of MDT and delayed androgen de...

Full description

Bibliographic Details
Main Authors: Elise De Bleser, Ruben Willems, Karel Decaestecker, Lieven Annemans, Aurélie De Bruycker, Valérie Fonteyne, Nicolaas Lumen, Filip Ameye, Ignace Billiet, Steven Joniau, Gert De Meerleer, Piet Ost, Renée Bultijnck
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
cost-utility analysis
metastasis-directed therapy
oligorecurrent
prostate cancer
oligometastasis
prostatic neoplasms
cost-effective
markov model
Online Access:https://www.mdpi.com/2072-6694/12/1/132

Internet

https://www.mdpi.com/2072-6694/12/1/132

Similar Items